Journal Basic Info

  • Impact Factor: 1.809**
  • H-Index: 6
  • ISSN: 2474-1655
  • DOI: 10.25107/2474-1655
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Sleep Medicine and Disorders
  •  Vascular Medicine
  •  Physical Medicine & Rehabilitation
  •  Cardio-Thoracic Surgery
  •  Nutrition and Food Science
  •  Veterinary Sciences
  •  Endocrinology
  •  Ophthalmology

Abstract

Citation: Ann Clin Case Rep. 2023;8(1):2474.DOI: 10.25107/2474-1655.2474

Llama-Derived Single-Chain Antibody for Targeting CD20 in B-Cell Lymphoma

Lu Y1, Li S2,3 and Wu W4*

1Neonatal Intensive Care Unit, The Second Hospital of Tianjin Medical University, China
2College of Life Sciences and Health, Wuhan University of Science and Technology, China
3Beijing Novaboody Biotechnological Ltd, China
4Department of Blood Transfusion, The 960th Hospital of the PLA Joint Logistics Support Force, China

*Correspondance to: Wen Wu 

 PDF  Full Text Research Article | Open Access

Abstract:

Objective: Since the approval of rituximab for the treatment of B cell non-Hodgkin lymphoma, the development of monoclonal Antibodies (mAbs) for cancer treatment has been subject to intense investigations. However, rituximab is expensive and has limited availability. Llama-derived singlechain antibody fragments are small molecules with several advantages over conventional antibodies, which have been widely used for cancer treatment. The present study aims to obtain a single-domain anti-CD20 antibody from an immune Llama phage display library. Methods: An immune Llama phage display library was constructed with phage display technology. The anti-CD20 single-domain Antibodies (sdAbs) were selected and the genes were cloned into expression vector pSJF2. The antibodies were efficiently expressed in Escherichia coli. The affinity and in vitro biological functions of different anti-CD20 sdAbs were measured by Biolayer interferometry. Result: Three anti-CD20 single-domain antibodies (anti-CD20e7, anti-CD20b1 and anti-CD20f1) were obtained which were produced at high yield in Escherichia coli and showed high affinity. Conclusion: These results, together with the ease of production, show that anti-CD20 VHHs are valuable candidates for the development of B-cell lymphoma therapies.

Keywords:

B-cell lymphoma; Immune phage display library; Llama-derived single-chain antibody fragments

Cite the Article:

Lu Y, Li S, Wu W. Llama-Derived Single-Chain Antibody for Targeting CD20 in B-Cell Lymphoma. Ann Clin Case Rep. 2023; 8: 2474..

Search Our Journal

Journal Indexed In

Articles in PubMed

Does Autoimmunity have a Role in Myoclonic Astatic Epilepsy? A Case Report of Voltage Gated Potassium Channel Mediated Seizures
 PubMed  PMC  PDF  Full Text
A New Minimally Invasive Procedure for Muscle, Back, Neck Pain and Radiculopathy - The Myofascial Nerve Block
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Treatment for Refractory Cardiogenic Shock Using Traditional Chinese Herbs Combined with Acupuncture: Two Case Reports
 Abstract  PDF  Full Text
Autoimmune Encephalitis Mimicking PRES: A Case Report and Literature Review
 Abstract  PDF  Full Text
View More...